IDEXX Laboratories Inc. (NASDAQ:IDXX) on Monday reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast.
The animal health company reported fourth-quarter 2025 earnings of $3.08 per share, up 18% year over year, beating the consensus of $2.94. Comparable earnings were $2.92 per share.
The company reported sales of $1.091 billion, beating the consensus of $1.073 billion, up 14% on a reported and 12% on an organic basis.
Segment Overview
Companion Animal Group (CAG) revenue was $998.5 million. The 14.7% growth was led by CAG Diagnostics’ recurring revenue growth of 12% (+10% organic), outpacing sector growth levels. U.S. growth was aided by increased diagnostic frequency, including early benefits from an aging pet population.
CAG Diagnostics’ capital instrument revenues of $58.13 million expanded 76% as reported and 69% on an organic basis, led by record quarterly instrument placements, including benefits from over 1,900 IDEXX inVue Dx placements and nearly 1,400 new and competitive Catalyst …